Chronic lymphocytic leukemia (CLL) is a low-grade lymphoid malignancy incurable with conventional modalities of chemotherapy. Strong and constitutive nuclear factor kappa B (NF-jB) activation is a characteristic of CLL cells. We examined the effects of a new NF-jB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on CLL cells. Dehydroxymethylepoxyquinomicin completely abrogated constitutive NF-jB activity and induced apoptosis of CLL cells. Apoptosis induced by DHMEQ was accompanied by downregulation of NF-jB-dependent antiapoptotic genes: c-IAP, Bfl-1, Bcl-X L and c-FLIP. Dehydroxymethylepoxyquinomicin also inhibited NF-jB induced by CD40 and enhanced fludarabine-mediated apoptosis of CLL cells. Results of this study suggest that inhibition of constitutive and inducible NF-jB by DHMEQ in combination with fludarabine is a promising strategy for the treatment of CLL.
Introduction
Chronic lymphocytic leukemia (CLL) is a low-grade B-cell malignancy predominantly affecting adults over the age of 50 years. The disease course is variable but remains incurable despite development of nucleoside analogues such as fludarabine and 2-chlorodeoxyadenosine (cladribine). 1 Development of a new treatment option based on the biological basis of CLL cells is needed to improve the prognosis of CLL. Most chemotherapeutic agents target the process of DNA replication and division of cells, therefore are more effective in tumor cells having high proliferation activity. These agents are not well suited for the treatment of CLL that shows not proliferation but instead an accumulation of cells through resistance to apoptosis. 2 Recently, treatment strategies to target molecules that support the maintenance and growth of the tumor cells have been pursued. 3 Molecular target therapy increases the specificity of the agent to tumor cells, thereby minimizes undesirable toxicity to normal cells and provides an opportunity to cure malignancies incurable by conventional chemotherapy. 4, 5 It is important for development of a new treatment strategy of CLL to clarify a common biological basis for deregulated apoptosis and to develop specific agents that target the required molecule(s). Despite the diversity in clinical manifestations of CLL, strong and constitutive nuclear factor kappa B (NF-kB) activity is reported to be a common characteristic of CLL cells. 6 NF-kB activation has been connected with control of apoptosis. 7, 8 This background suggests that in CLL cells, constitutively active NF-kB antagonizes apoptotic pathways leading to inappropriate survival of tumor cells. Recent studies using antibody against CD40 ligand (CD40L), which inhibits CD40 signaling, and a proteasome inhibitor support this hypothesis. 6, 9, 10 If so, targeting the NF-kB pathway and inhibition of NF-kB activity is a logical strategy to treat CLL.
Dehydroxymethylepoxyquinomicin (DHMEQ) is a new NFkB inhibitor that is a 5-dehydroxymethyl derivative of a novel compound epoxyquinomicin C. 11 We showed that DHMEQ inhibits nuclear translocation of NF-kB. 12 In the present study, using a new NF-kB inhibitor DHMEQ, we present data that indicate that constitutive NF-kB activation supports survival of CLL cells by induction of antiapoptotic genes. Dehydroxymethylepoxyquinomicin inhibited NF-kB activity induced by CD40 and enhanced fludarabine-mediated apoptosis of CLL cells, suggesting that inhibition of constitutive and inducible NF-kB by DHMEQ in combination with fludarabine is a promising strategy for the future treatment of CLL.
Materials and methods

Patients
All patients (n ¼ 15) were previously diagnosed as having B-cell CLL according to established clinical and laboratory criteria. 13 Patients were either untreated (n ¼ 7) or had received cytoreductive chemotherapy before investigation (n ¼ 8). Relevant clinical and laboratory data of the patients are included in Table 1 .
Separation procedures and culture
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples obtained after informed consent using gradient centrifugation with Lymphoprep (AXIS SHIELD PoC AS, Oslo, Norway). Chronic lymphocytic leukemia cells were purified using a Dynal B-cell-negative isolation kit (Dynal Biotech, Oslo, Norway). This method produced more than 95% pure population of CLL cells expressing both CD19 and CD5 (mean 97.8%), as determined by flow cytometry using antibodies anti-CD19/FITC and anti-CD5/PE (Dako, Kyoto, Japan). We purified normal B cells using the same method, which produced more than 90% pure population of B cells (mean 92.7%), assessed by flow cytometry staining with anti-CD19/FITC antibody (Dako, Kyoto, Japan). Cells were cultured at 371C with 5% CO 2 in RPMI 1640 supplemented with 20% fetal bovine serum and antibiotics.
Chemicals
Dehydroxymethylepoxyquinomicin is an NF-kB inhibitor that blocks nuclear translocation of NF-kB. 11, 12 An active metabolite of fludarabine, 2-fluoroadenine-9-b-D-arabinofuranoside (F-ara-A), was purchased from Sigma (St Louis, MO, USA). Dehydroxymethylepoxyquinomicin and F-ara-A were dissolved with dimethylsulfoxide (DMSO) and used for experiments at indicated concentrations. Bisbenzimide H 33342 fluorochrome (Hoechst 33342) and caspase-3 inhibitor Z-Asp-Glu-Val-Asp-(DEVD)-FMK were purchased from Calbiochem (Bad Soden, Germany).
Electrophoretic mobility shift analysis
Electrophoretic mobility shift analysis (EMSA) was carried out according to the methods described previously.
14 Doublestranded oligonucleotide probes containing the mouse immunoglobulin-k light-chain NF-kB consensus site were purchased from Promega (Madison, WI, USA). Antibodies used for supershift assays were as follows: NF-kB p50 (C-19) goat polyclonal antibody, NF-kB p65 (C-20) and RelB (C-19) rabbit polyclonal antibody and mouse monoclonal antibodies for c-Rel (B-6) and NF-kB p52 (C-5) (all from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Cell viability assay
Effects of DHMEQ on cell viability were assayed by color reaction with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT assay) as described previously. 15 After incubation with DHMEQ at the indicated concentrations and time points, 2 Â 10 5 cells treated by MTT solution were measured by a microplate reader (Bio-Rad, Richmond, CA, USA) at a reference wavelength of 570 nm and test wavelength of 450 nm. The cell viability was expressed as a percentage of the DMSO-treated control samples.
Apoptosis and analysis of caspase activity
To quantify apoptosis, cells were labeled with FITC-conjugated Annexin V (BD Biosciences, Palo Alto, CA, USA) followed by flow cytometric analysis. For analysis of morphological changes of nuclei, cells were stained by 10 mM Hoechst 33342, and photographed through a UV filter. Detection of cleaved caspase 3 was performed by immunohistochemistry. Antibodies used in these experiments were as follows: rabbit polyclonal antibody for cleaved caspase 3 (Asp175) (Cell Signaling, Beverly, MA, USA) and for glyceraldehyde phosphate dehydrogenase (FL335) (Santa Cruz Biotechnology Inc.). Mouse monoclonal antibody for Fas (CH-11) (Medical and Biological Laboratories Co., Ltd, Nagoya, Japan) was used for stimulation of Fas.
Real-time PCR analysis
Total RNA from isolated CLL cells was extracted using ISOGEN (Nippon Gene Co., Tokyo, Japan) according to the manufacturer's instructions. Single-stranded cDNA was synthesized using TaqMan Reverse Transcription Reagents (Applied Biosystems, Norwalk, CT, USA). The primers for Bcl-X L ; Hs00236329_m1 (BCL2L1) c-IAP; Hs00154109_m1 (BIRC3), Bfl-1; Hs00187845_m1 (BCL2A1) and c-FLIP; Hs00153439_m1 (CFLAR) were purchased from Applied Biosystems (Tokyo, Japan). The conditions of real-time PCR were as follows: 1 ml of cDNA was added to 25 ml of TaqMan Gene Expression Assays and made up to a total volume of 50 ml with distilled water for each reaction. Thermal cycler conditions were 2 min at 501C, 10 min at 951C and then 40 cycles of 15 s at 951C followed by 1 min at 601C. Results were collected and analyzed using an ABI PRISM 7000 sequence detection system (Applied Biosystems).
Statistical analysis
Differences between mean values were assessed by two-tailed ttest. A P-value o0.05 was considered to be statistically significant.
Results
Effects of DHMEQ on constitutive NF-kB activity in primary CLL cells
First we examined the effect of DHMEQ on constitutive NF-kB activity and its time course in CLL cells (n ¼ 5; #1, 2, 6, 7 and 14) by EMSA. As described previously, high NF-kB DNA binding activity was detected in nuclear extracts from CLL cells. 16 Treatment with 10 mg/ml of DHMEQ almost completely abrogated NF-kB DNA binding activity within 2 h. DNA binding activity of untreated CLL cells served as controls. Representative results (#7 and 14) are shown in Figure 1a . Supershift analysis of CLL cells (n ¼ 5; #1, 2, 6, 7 and 15) showed that NF-kB DNA binding activity consists of p50 homodimer (lower band) and p50/p65 heterodimer (upper band). Representative results (#2 and 15) are shown in Figure 1b . We next examined the effect of DHMEQ on constitutive NF-kB activity in all CLL cases studied (n ¼ 15). Treatment with 10 mg/ml of DHMEQ completely blocked NF-kB DNA binding activity in all cases. The results of 10 cases are shown in Figure 1c . 
DHMEQ selectively induces apoptosis of CLL cells
To evaluate an effect of constitutively active NF-kB on the survival of CLL cells, we treated CLL cells (n ¼ 15) by DHMEQ and examined their viability. MTT assays revealed that DHMEQ reduced the viability of all CLL cells examined in a dose ( 2 mg/ml, 86.275.9%, 5 mg/ml, 48.2716.8%, 10 mg/ml, 44.37 16.3%) (Figure 2a ) and time (24 h, 44.3716.3%, 48 h, 33.5717.4%) (Figure 2b ) dependent manner and the effects were significant at all drug concentrations and incubation times tested (Po0.01). The effects were not significant in control PBMC (n ¼ 5) and purified peripheral blood B cells (n ¼ 3) as shown in Figure 2a and b.
Constitutively active NF-kB has been thought to antagonize apoptotic pathways leading to inappropriate survival of tumor cells. 7, 8 Thus, we examined whether DHMEQ induces apoptosis of CLL cells (n ¼ 5; #3, 6, 7, 10 and 11). 
DHMEQ downregulates expression of antiapoptotic genes
In order to understand the molecular mechanisms of apoptosis in CLL cells after NF-kB inhibition by DHMEQ, we next examined the changes of expression level of antiapoptotic genes, Bcl-X L , c-IAP, c-FLIP and Bfl-1, after DHMEQ treatment in CLL cells (n ¼ 8; #2, 3, 6, 7, 9, 11, 13 and 15) by real-time PCR. These antiapoptotic genes have been reported to be under the control of NF-kB. 7 The results shown in Figure 4 demonstrate significant reduction in the following genes: Bcl-X L (53.4735.3% reduction, Po0.01), c-IAP (93.377.4% reduc- 
DHMEQ enhances the antitumor effect of fludarabine and inhibits CD40-mediated induction of NF-kB
We next examined whether DHMEQ could enhance the effects of fludarabine, a key chemotherapeutic agent for CLL. We first incubated CLL cells (n ¼ 5; #4, 6, 10, 11 and 14) with DHMEQ, F-ara-A or F-ara-A in the presence of 5 mg/ml of DHMEQ and calculated the IC 50 (the concentration that results in 50% viability of control). F-ara-A in combination with DHMEQ significantly enhanced the IC 50 of F-ara-A compared with F-ara-A alone (5.075.1 vs 11.375.3 mg/ml, P ¼ 0.03), suggesting that DHMEQ enhanced the antigrowth effect of fludarabine on CLL cells. IC 50 of DHMEQ was 9.674.0 mg/ml. Representative data are shown as Figure 5a . Although experimental conditions are different compared with previous reports, IC 50 for F-ara-A (#4; 13.2 mg/ml, #6; 12.4 mg/ml, #10; 7.8 mg/ml, #11; 12.7 mg/ml, #14; 4.0 mg/ml) indicates that cases other than #14 show potential resistance for fludarabine. 
Effect of DHMEQ on CLL cells
We further explored whether the combined effect of F-ara-A and DHMEQ results in enhanced induction of apoptosis in CLL cells. The combined treatment showed a significant increase in the number of Annexin V-positive cells when compared with F-ara-A alone (DHMEQ 30.972.2%; F-ara-A 19.9712.6%; DHMEQ plus F-ara-A 53.3710.2%, P ¼ 0.03) (Figure 5b) . The combined treatment also showed a significant increase in the expression of the cleaved form of caspase 3 and in the fragmentation or condensation of nuclei. Representative results (#11) are shown in Figure 5c and d. These results indicate that DHMEQ enhances fludarabine-mediated apoptosis of CLL cells.
As CD40 signals were reported to play an important role in the survival of CLL cells in vivo, we examined the effect of DHMEQ on CD40-mediated NF-kB induction in CLL cells (n ¼ 5; #2, 6, 7, 9 and 13). The mean percentage of induction of NF-kB binding activity was 224.5765.0% and significant (Po0.01) when the intensities of the unstimulated samples were compared with those of CD40-stimulated samples by densitometry. Dehydroxymethylepoxyquinomicin abrogated both constitutive and inducible NF-kB by CD40 activation in CLL cells. Representative results (#2, 6 and 7) are shown in Figure 6 .
Discussion
Although previous work using a decoy oligonucleotide for NFkB indicated that inhibition of NF-kB alone is not sufficient to induce apoptosis of CLL cells, 16 recent studies using proteasome inhibitors or an antibody against CD40L suggest the importance of NF-kB in the survival of CLL cells. 6, 9, 10 Our data clearly show that constitutive activation of NF-kB supports survival of CLL 
Effect of DHMEQ on CLL cells
cells. Discrepancies between a previous report using a decoy oligonucleotide for NF-kB and ours appear to reside in the experimental conditions and inhibitors used. Inhibition of NFkB by DHMEQ is prompt and complete. On the other hand, inhibition of NF-kB by transduced decoy oligonucleotide appears to occur gradually. Furthermore, complete inhibition of NF-kB by the decoy oligonucleotide is difficult because of its limited transduction efficiency. Our results also provide insights into the mechanism of DHMEQ-mediated apoptosis induction in CLL cells. Inhibition of NF-kB by DHMEQ downregulated the expression of antiapoptotic genes Bcl-X L , c-IAP1, c-FLIP and Bfl-1, suggesting that DHMEQ-mediated apoptosis is associated with downregulation of NF-kB-dependent genes that regulate apoptosis. Recent studies, which stress the importance of these genes on regulation of CLL cell survival, support this notion. 18, 19 This also suggests that the survival of CLL is based on a balance between proapoptotic and antiapoptotic genes. Dehydroxymethylepoxyquinomicin is thought to block antiapoptotic activity that permits the survival of CLL cells, resulting in dominance of proapoptotic activities.
The results of this study indicate that DHMEQ is a promising compound to induce NF-kB inhibition by a low molecular weight compound for the treatment of CLL. The inhibitory effect of DHMEQ on NF-kB is prompt and definitive even against the strong constitutive NF-kB activity of CLL cells. Dehydroxymethylepoxyquinomicin treatment can induce apoptosis of CLL cells within 24-48 h. Dehydroxymethylepoxyquinomicin completely abrogated NF-kB activity and reduced viability of CLL cells in all cases studied, which is independent of previous treatment. Unique properties of DHMEQ may minimize adverse effects on normal cells. Peripheral blood mononuclear cells and purified B cells are resistant to apoptosis by DHMEQ treatment.
This resistance of resting cells to DHMEQ appears to be an important feature to avoid undesired effects.
In this study, we evaluated the combined effect of DHMEQ and fludarabine on survival of CLL cells. Dehydroxymethylepoxyquinomicin enhanced the effect of fludarabine on CLL cell, but the mechanisms of action of these two agents do not overlap. Blockade of NF-kB by DHMEQ inhibits translocation of NF-kB into the nucleus and appears to induce apoptosis by downregulation of NF-kB-dependent antiapoptotic genes. On the other hand, fludarabine exerts its effects by inhibition of DNA and RNA synthesis. 20 As CLL cells reside in a quiescent state, inhibition of RNA synthesis and depletion of proteins appear to be essential for the cytotoxic action of fludarabine. 21 Dehydroxymethylepoxyquinomicin-mediated inhibition of NF-kB may enhance the effect of fludarabine against CLL cells, especially in vivo. CD40 signals triggered by CLL cells themselves or by bystander normal T or B cells, expressing CD40L, drive NF-kB activity and are thought to support survival of CLL cells. 6, 19 It has been reported that activation of CD40 inhibits fludarabine-induced apoptosis of CLL cells. Activation of the NF-kB pathway, which mainly involves IkB, is one mechanism of this inhibition. Activation of NF-kB triggered by CD40 is mediated by degradation of IkB and may not require protein synthesis. Thus, inhibition of protein synthesis by fludarabine through depletion of mRNA should not affect NFkB activation by CD40. 21 In this study, we showed that DHMEQ could inhibit CD40-mediated induction of NF-kB in CLL cells. Therefore, DHMEQ appears to be a suitable compound to be used in combination with fludarabine.
In conclusion, we provided data that suggest that constitutive NF-kB activation supports survival of CLL cells and that inhibition of NF-kB by DHMEQ is a promising strategy to treat CLL. Dehydroxymethylepoxyquinomicin-mediated inhibition of NF-kB may contribute to enhance effects of fludarabine by blocking CD40-mediated NF-kB activation of CLL cells especially in vivo. ) were crosslinked by 500 ng/ml of anti-CD40 agonistic mouse antibody (Immunotech, Marseille Cedex, France) for 1 h and treated with 10 mg/ ml of DHMEQ for 5 h. CLL cells crosslinked by isotype-matched IgG (Dako) served as controls. Two micrograms of nuclear extracts were examined for NF-kB binding activity by electrophoretic mobility shift analysis using a radiolabeled NF-kB probe.
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